Krista Qualmann on Genetic Counseling and Testing for Patients with Cancer

Video

Krista Qualmann discusses hereditary cancer syndromes.

Krista Qualmann, MS, CGC, Memorial Hermann Mischer Neuroscience Institute at the Texas Medical Center and UTHealth, discusses hereditary cancer syndromes.

About 5% to 10% of cancers are caused by single-gene disorders. These hereditary cancer syndromes are most well-known for causing cancers such as breast cancer, ovarian cancer and endometrial cancer. They can also have a hand in colon cancer, brain tumors and melanoma.

Recent Videos
Medium closeup shot of a women in front of a dark blue background with graphics that read "All in Against Cancer" and "Ochsner Health"
Image of a woman in front of a blue Oncology Nursing News-branded backdrop.
Related Content
Blue rendering of a person with breast tissue highlighted in orange

T-DM1 Further Improves DFS and OS vs Trastuzumab in HER2-Positive Early Breast Cancer

Bridget Hoyt
February 20th 2025
Article

T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Simple line illustration of the female reproductive system with a tumor on the uterine lining, on a light blue background

Pembrolizumab Shows ORR, Tolerability in Previously Treated Gynecologic Cancer

Kristi Rosa
February 11th 2025
Article

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously treated CCGC.

The Vitals

Jacki Garcia and Kristin Hendrickson on Navigating Patients Through Phase 0 Trials

Lindsay Fischer
July 15th 2023
Podcast

Jacki Garcia, RN, BSN, CNRN; and Kristin Hendrickson, BA, RN, discuss phase 0 trials and how they can help expedite the research process for brain cancer therapies.

light blue background with a white outline indicating a clipboard that says FDA

FDA Grants Breakthrough Status to Endometrial Cancer Assay

Kyle Doherty
February 9th 2025
Article

The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer.

Blue diagram of a human's bones and tissue, with the breast tissue and tumor in focus

Pertuzumab Biosimilar BLA for HER2+ Breast Cancer Accepted by FDA

Chris Ryan
February 7th 2025
Article

After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.